ERCC1 and ovarian carcinoma: 45), ovarian cancer (n.27) and pancreatic cancer (n.17), but treated with cisplatin-containing regimens, has shown that median survival of patients with low level of ERCC1 expression was 18 months in comparison to 12 months of those with high level of expression [30].